A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

Autor: Matthew Winter, Rob Coleman, Jessica Kendall, Carlo Palmieri, Chris Twelves, Sacha Howell, Iain MacPherson, Caroline Wilson, Kash Purohit, Jacqui Gath, Christine Taylor, Richard Eastell, Geraldine Murden, Sarah R. Brown, Emma Rathbone, Janet Brown

Publikováno v: Journal of Bone Oncology, Vol 35, Iss , Pp 100442- (2022)

Background: Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of bone metastases to reduce skeletal morbidit

Externí odkaz: https://doaj.org/article/f4c9910e2ee343c2970db1a4f3955768

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

Autor: Chris Twelves, Sarah Brown, Sacha J Howell, Robert E. Coleman, Emma Rathbone, Janet E. Brown, Iain R. Macpherson, Amber Reid, Louise Flanagan, Carlo Palmieri, Jessica Kendall, Anjana Anand

Publikováno v: Trials, Vol 21, Iss 1, Pp 1-10 (2020)
Trials
Coleman, R, Brown, J, Rathbone, E, Flanagan, L, Reid, A, Kendall, J, Howell, S, Twelves, C, Palmieri, C, Anand, A, MacPherson, I & Brown, S 2020, ' CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) : Study protocol for a phase IB/IIA randomised controlled trial ', Trials, vol. 21, no. 1, 89 . https://doi.org/10.1186/s13063-019-3643-6
TRIALS

Background A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70% of patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::002e969a0f5dd641b2ac680387615e3e
https://eprints.whiterose.ac.uk/155798/1/document.pdf

Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis

Autor: Emma, Rathbone, Lindsay, Durant, James, Kinsella, Antony R, Parker, Ghaniah, Hassan-Smith, Michael R, Douglas, S John, Curnow

Publikováno v: Journal of neurology, neurosurgery, and psychiatry. 89(10)

To determine whether the ratio of cerebrospinal fluid (CSF) immunoglobulin kappa to lambda light chains at time of multiple sclerosis (MS) diagnosis predicts disease progression and whether this was intrinsic to CSF plasmablasts.CSF and peripheral bl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::13ab6832e63afdae6cf766262cb07826
https://pubmed.ncbi.nlm.nih.gov/29764926

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

Autor: Peter Barrett-Lee, Victoria Liversedge, M. Gil, Caroline Wilson, Robert Grieve, D. Dodwell, Roger Burkinshaw, Helen Marshall, David Cameron, Emma Rathbone, Samantha Hinsley, Richard Bell, Diana Ritchie, M. Keane, Robert E. Coleman

Publikováno v: The Lancet Oncology. 15:997-1006

Summary Background The role of adjuvant bisphosphonates in early breast cancer is uncertain. We therefore did a large randomised trial to investigate the effect of the adjuvant use of zoledronic acid on disease-free survival (DFS) in high-risk patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440de9c767557fa85d8c0daadf72f6db
https://doi.org/10.1016/s1470-2045(14)70302-x

Osteonecrosis of the Jaw and Oral Health–Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04)

Autor: Victoria Liversedge, Robert E. Coleman, Prabir Chakraborti, Saiqa Spensley, Richard Bell, Emma Rathbone, Geraldine A. Murden, H Marshall, R.K. Agrawal, Michelle Collinson, Frances Yuille, Rema Jyothirmayi, Janet E. Brown, David Cameron

Publikováno v: Journal of Clinical Oncology. 31:2685-2691

Purpose In patients with early breast cancer, adjuvant zoledronic acid (zoledronate) may reduce recurrence and improve survival. However, zoledronate is associated with the occasional development of osteonecrosis of the jaw (ONJ). We report on the fr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0605f02d3ffdee1fcaecd695b3a54e20
https://doi.org/10.1200/jco.2012.46.4792